Ipratropium Steri-Neb (Ipratropium Bromide)

Ipratropium bromide blocks muscarinic M3 receptors on airway smooth muscle, preventing acetylcholine‑induced contraction. This antagonism reduces bronchoconstriction and mucus secretion, resulting in bronchodilation and improved airflow in obstructive lung conditions.

The dose of Ipratropium Steri‑Neb is determined by the prescribing clinician based on the patient’s condition, severity, and response to therapy. Healthcare professionals select the appropriate volume and frequency of nebulized solution for each individual.

Safety data for ipratropium bromide in pregnancy and lactation are limited, and the product is classified as “unknown” for pregnancy. Women who are pregnant, planning to become pregnant, or breastfeeding should discuss potential risks and benefits with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Ipratropium is an anticholinergic bronchodilator, whereas agents like albuterol are beta‑2 agonists. Ipratropium provides longer‑lasting bronchodilation with fewer cardiac side effects, but it may be less rapid in onset compared with short‑acting beta‑agonists. Often, clinicians combine both classes for additive effect.

Store the nebulizer solution at room temperature, away from direct sunlight and moisture. Keep the container tightly closed when not in use and protect it from freezing. Follow any additional handling instructions provided on the label to maintain product stability.

Ipratropium Steri‑Neb is administered by nebulization. The prescribed volume of solution is placed in a compatible nebulizer device, and the patient inhales the aerosolized medication through a mouthpiece or mask, typically for several minutes per dose as directed by a healthcare professional.

Serious adverse events include paradoxical bronchospasm, severe allergic reactions such as anaphylaxis, and urinary retention that may require medical attention. Patients should seek immediate care if they experience sudden worsening of breathing, swelling, rash, or difficulty urinating.

Ipratropium Steri‑Neb should be avoided in individuals with known hypersensitivity to ipratropium bromide or any formulation components, those with narrow‑angle glaucoma, significant urinary retention, or prostate enlargement that could be worsened by anticholinergic effects. Clinicians must evaluate each patient’s medical history before prescribing.